Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A
about
Hemophilia A: an ideal disease to correct in uteroGene therapy for hemophiliaChemical chaperones improve protein secretion and rescue mutant factor VIII in mice with hemophilia ADevelopment and characterization of recombinant ovine coagulation factor VIIIThe F309S mutation increases factor VIII secretion in human cell lineLentiviral vector platform for production of bioengineered recombinant coagulation factor VIIIExpanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitorsEnhanced biosynthesis of coagulation factor VIII through diminished engagement of the unfolded protein response.Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery.Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia AEngineering Factor Viii for Hemophilia Gene Therapy.Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment.Delivery of nucleic acid therapeutics by genetically engineered hematopoietic stem cells.Potential for cellular stress response to hepatic factor VIII expression from AAV vectorSK-HEP cells and lentiviral vector for production of human recombinant factor VIII.Engineered Hematopoietic Stem Cells as Therapeutics for Hemophilia A.Enhanced plasma factor VIII activity in mice via cysteine mutation using dual vectors.
P2860
Q26852638-308D01A3-1B1D-404E-9CED-3EFF7C744CA3Q28081911-1C3EF321-FB40-4640-B7C4-485B7EC583ACQ28483362-D6599F1A-974C-48C7-BF12-41905AA709C6Q28485123-96C1AE5E-D035-4D4E-BCBA-828998A478BDQ28833603-35524B8F-B4F5-4D2D-8004-39C7636914F0Q34556878-018B6B1E-342C-4169-A15D-5C3EBBD13044Q34964772-FA021F21-5750-479F-9131-E27C7C9D70A0Q35085180-D4F3E35B-B08A-4CBE-A837-0F28A8E31CECQ35184180-B244B1D9-121D-4724-8946-78EFA066AA0BQ36553800-A94559F6-EBFA-4C0B-8C0A-5456ACB25720Q36737263-D602B4AE-A133-4461-BBC4-375016F64B8AQ37075305-F10A6B47-2BD3-47BF-9ECE-6E9D1057264BQ37792339-BAA18639-35E1-452C-886F-8CA577167526Q39293496-2A9A8B61-F6EC-4B40-AE78-7CACA2788F25Q39367231-95966B89-7ECF-48D1-ACC9-8CA9EB7C1B28Q42975417-D1A0D246-8831-440C-8BD4-BD46050C0B13Q43760741-2A1D380F-780C-49CD-A2F3-87ED0C97C01E
P2860
Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Comparison of factor VIII tran ...... n gene therapy of hemophilia A
@ast
Comparison of factor VIII tran ...... n gene therapy of hemophilia A
@en
type
label
Comparison of factor VIII tran ...... n gene therapy of hemophilia A
@ast
Comparison of factor VIII tran ...... n gene therapy of hemophilia A
@en
prefLabel
Comparison of factor VIII tran ...... n gene therapy of hemophilia A
@ast
Comparison of factor VIII tran ...... n gene therapy of hemophilia A
@en
P2093
P2860
P921
P356
P1433
P1476
Comparison of factor VIII tran ...... n gene therapy of hemophilia A
@en
P2093
Bagirath Gangadharan
Christopher B Doering
David A McCarty
Elisabeth H Javazon
Gabriela Denning
H Trent Spencer
Kerry L Dooriss
P2860
P304
P356
10.1089/HUM.2008.150
P577
2009-05-01T00:00:00Z